Acetyl-leucine slows disease progression in lysosomal storage disorders.

GM2 gangliosidosis Niemann-Pick disease type C acetyl-leucine lysosomal storage diseases miglustat

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2021
Historique:
received: 28 04 2020
revised: 15 07 2020
accepted: 21 07 2020
entrez: 19 3 2021
pubmed: 20 3 2021
medline: 20 3 2021
Statut: epublish

Résumé

Acetyl-dl-leucine is a derivative of the branched chain amino acid leucine. In observational clinical studies, acetyl-dl-leucine improved symptoms of ataxia, in particular in patients with the lysosomal storage disorder, Niemann-Pick disease type C1. Here, we investigated acetyl-dl-leucine and its enantiomers acetyl-l-leucine and acetyl-d-leucine in symptomatic

Identifiants

pubmed: 33738443
doi: 10.1093/braincomms/fcaa148
pii: fcaa148
pmc: PMC7954382
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcaa148

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202834/Z/16/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Sci Transl Med. 2016 Sep 7;8(355):355ra118
pubmed: 27605553
Sci Rep. 2017 Nov 21;7(1):15944
pubmed: 29162837
J Cell Biol. 2012 Nov 26;199(5):723-34
pubmed: 23185029
Anal Biochem. 2004 Aug 15;331(2):275-82
pubmed: 15265733
J Clin Invest. 2014 Mar;124(3):1320-8
pubmed: 24487591
J Biol Chem. 2007 Aug 17;282(33):24131-45
pubmed: 17580304
J Biol Chem. 2010 Nov 26;285(48):37415-26
pubmed: 20864542
Am J Pathol. 1982 Aug;108(2):140-9
pubmed: 6765731
Hum Mol Genet. 2012 Jun 15;21(12):2651-62
pubmed: 22437840
Biochim Biophys Acta. 1980 Sep 8;619(3):669-79
pubmed: 6257302
Prog Brain Res. 2006;151:157-203
pubmed: 16221589
Eur J Pharmacol. 2015 Dec 15;769:342-9
pubmed: 26607469
Eur J Neurosci. 2001 Feb;13(4):735-48
pubmed: 11207808
PLoS One. 2013 Jun 26;8(6):e67473
pubmed: 23840713
Structure. 2008 Dec 10;16(12):1849-59
pubmed: 19081061
Science. 2000 Dec 1;290(5497):1717-21
pubmed: 11099404
Arch Biochem Biophys. 1985 Dec;243(2):542-55
pubmed: 4083900
Adv Physiol Educ. 2006 Dec;30(4):145-51
pubmed: 17108241
J Biol Chem. 1992 Mar 5;267(7):4889-96
pubmed: 1537866
Am J Pathol. 2016 Jun;186(6):1582-97
pubmed: 27083515
J Proteome Res. 2016 Oct 7;15(10):3511-3527
pubmed: 27503774
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6388-93
pubmed: 10339597
Orphanet J Rare Dis. 2018 Aug 16;13(1):143
pubmed: 30115089
Neuropediatrics. 2020 Dec;51(6):450-452
pubmed: 32892336
Curr Neuropharmacol. 2012 Dec;10(4):393-403
pubmed: 23730261
J Biol Chem. 1999 Apr 23;274(17):11647-52
pubmed: 10206976
J Nutr. 2005 Jun;135(6 Suppl):1527S-30S
pubmed: 15930464
PLoS One. 2013 Dec 18;8(12):e82685
pubmed: 24367541
Lancet Neurol. 2007 Sep;6(9):765-72
pubmed: 17689147
Neurobiol Dis. 2014 Jul;67:9-17
pubmed: 24631719
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):132-40
pubmed: 19415691
Nat Genet. 1995 Oct;11(2):170-6
pubmed: 7550345
J Biochem. 2001 Jun;129(6):875-80
pubmed: 11388901
J Neuropathol Exp Neurol. 2000 Dec;59(12):1106-17
pubmed: 11138930
PLoS One. 2020 Feb 27;15(2):e0229585
pubmed: 32108176
Traffic. 2010 Apr;11(4):419-28
pubmed: 20059748
PLoS One. 2015 Mar 24;10(3):e0120891
pubmed: 25803613
J Clin Med. 2020 Apr 08;9(4):
pubmed: 32276303
J Neurol. 2013 Oct;260(10):2556-61
pubmed: 23835634
Trends Endocrinol Metab. 2012 Sep;23(9):420-8
pubmed: 22819213
Neurology. 2015 Oct 20;85(16):1368-75
pubmed: 26400580
J Inherit Metab Dis. 2020 May;43(3):574-585
pubmed: 31707734
Amino Acids. 2016 Apr;48(4):1045-1058
pubmed: 26724922
Cell Metab. 2019 Jan 8;29(1):192-201.e7
pubmed: 30197302
Anal Chim Acta. 2012 May 21;727:8-12
pubmed: 22541816
Nat Rev Drug Discov. 2018 Dec;17(12):865-886
pubmed: 30393373
Glia. 1997 Sep;21(1):92-8
pubmed: 9298851
Clin Transl Med. 2016 Dec;5(1):25
pubmed: 27465020
Diabetes Obes Metab. 2008 Feb;10(2):159-66
pubmed: 18190430
Cerebellum Ataxias. 2016 Apr 12;3:8
pubmed: 27073690
Theor Biol Med Model. 2015 May 29;12:10
pubmed: 26022743

Auteurs

Ecem Kaya (E)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

David A Smith (DA)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Claire Smith (C)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Lauren Morris (L)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Tatiana Bremova-Ertl (T)

Department of Neurology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, 81377 München, Germany.

Mario Cortina-Borja (M)

Population, Policy and Practice Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK.

Paul Fineran (P)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Karl J Morten (KJ)

Nuffield Department of Women's and Reproductive Health, University of Oxford, John Radcliffe Hospital OX3 9DU, Oxford, UK.

Joanna Poulton (J)

Nuffield Department of Women's and Reproductive Health, University of Oxford, John Radcliffe Hospital OX3 9DU, Oxford, UK.

Barry Boland (B)

Department of Pharmacology and Therapeutics, Western Gateway Building, College of Medicine and Health, University College Cork, Cork, T12XF62, Ireland.

John Spencer (J)

Department of Chemistry, School of Life Sciences, University of Sussex, Brighton, BN1 9RH UK.

Michael Strupp (M)

Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, 81377 München, Germany.

Frances M Platt (FM)

Department of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Classifications MeSH